BPC-157 & TB-500 vs SS-31 (Elamipretide)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
BPC-157 & TB-500
Known as the 'Wolverine Stack,' this popular combination pairs two powerful healing peptides. BPC-157 and TB-500 work synergistically to promote tissue repair, reduce inflammation, and accelerate recovery from injuries.
Full details →SS-31 (Elamipretide)
SS-31, also known as Elamipretide or Bendavia, is a mitochondria-targeted tetrapeptide. It has been studied extensively for mitochondrial diseases, heart failure, and age-related decline in mitochondrial function.
Full details →Side-by-Side Comparison
| Aspect | BPC-157 & TB-500 | SS-31 (Elamipretide) |
|---|---|---|
| Mechanism | BPC-157 upregulates growth factor expression and promotes angiogenesis, while TB-500 promotes cell migration and differentiation through actin regulation. Together, they enhance wound healing, reduce scar tissue formation, and support musculoskeletal recovery through complementary pathways. | Concentrates in the inner mitochondrial membrane where it binds to cardiolipin, stabilizing electron transport chain function, reducing reactive oxygen species, and improving ATP production efficiency. |
| Typical Dosage | Typical research protocols: BPC-157 at 250-500mcg daily combined with TB-500 at 2-2.5mg twice weekly during loading phase, then 2mg every 2 weeks for maintenance. | Clinical trials have used IV infusions of 0.25mg/kg for acute conditions. Subcutaneous dosing protocols for research use typically range from 1-5mg daily. |
| Administration | Both peptides administered via subcutaneous injection. Some protocols suggest injecting near injury sites for localized effects. Can be injected separately or as a pre-mixed blend. | Can be administered IV or subcutaneously. Most clinical research has used IV administration for cardiac conditions. |
| Side Effects | Generally well-tolerated. May include mild nausea, temporary fatigue, headache, or localized irritation at injection sites. | Generally well-tolerated. Clinical trials reported injection site reactions and occasional headache. |
| Best For |
What They Have in Common
Both BPC-157 & TB-500 and SS-31 (Elamipretide) are commonly used for: